The global recto-vaginal fistula treatment market was valued at US$ 550.8 Mn in 2020.
The global recto-vaginal fistula treatment market was valued at US$ 550.8 Mn in 2020
It is estimated to expand at a CAGR of 5.7% from 2022 to 2031
The global recto-vaginal fistula treatment market is expected to cross the value of US$ 1 Bn by the end of 2031
Download Sample @ https://qyresearchmedical.com/sample/111471
Market Scenario
Elective procedures have been postponed indefinitely in the recto-vaginal fistula treatment market due to the ongoing coronavirus pandemic. Healthcare stakeholders are increasing the availability of tests such as contrast tests, blue dye test, and CT scan to identify fistulas. However, the high number of morbidity and mortality even after recto-vaginal fistula treatment is emerging as a challenge to healthcare practitioners. Hence, practitioners should increase awareness about pre-appointment restrictions, considerations for surgery and listing key medical information to enable proper diagnosis of recto-vaginal fistula. It has been found that presence of cancerous tumor in regions such as uterus, rectum, vagina, anal canal or cervix, can lead to the development of recto-vaginal fistula.
COVID-19 Impact
The rise in prevalence of Crohn’s disease resulting in the occurrence of recto-vaginal fistula is driving the global recto-vaginal fistula treatment market. Crohn’s disease can be defined as an inflammatory bowel disease, wherein there is an inflammation of the digestive tract lining. A large number of women suffering from Crohn’s disease never develop recto-vaginal fistula. However, suffering from Crohn’s disease increases the risk of this condition. Hence, the prevalence of recto-vaginal fistula is projected to rise during the forecast period, owing to the increase in incidence of Crohn’s disease.
Delivery-related injuries is a most common factor causing recto-vaginal fistulas. This includes perineum tear that extends to the bowel or an episiotomy infection, which is a surgical incision conducted to enlarge the perineum during the course of vaginal delivery. These could occur post a long, difficult, or otherwise obstructed labor. These kinds of fistula could also comprise injury to anal sphincter, the muscle rings at the end of the rectum that aids a person to hold. Hence, the incidence rate of recto-vaginal fistula is likely to increase due to rise in the rate of childbirth injuries during the forecast period. Such findings are steering the growth of the recto-vaginal fistula treatment market.
COVID-19 Pandemic
Stakeholders in the recto-vaginal fistula treatment market are adopting contingency planning to prevent disruption across patient demands, supply of materials, and availability of diagnostic services. Since elective procedures have been postponed indefinitely due to the ongoing coronavirus pandemic, medical practitioners are increasing awareness about different tests for identifying fistulas, medications, and lifestyle or home remedies to reduce burden on healthcare facilities. As such, telehealth and mobile apps are anticipated to register high growth post the pandemic. Healthcare stakeholders are striking a balanced relationship with suppliers and ecosystem partners to improve medical outcomes. They are increasing the availability of life-altering therapeutics.
To understand how our report can bring difference to your business strategy, Ask for a brochure
Healthcare Stakeholders Invest in R&D to Increase Treatment Options
Recto-vaginal fistula can be described as abnormal epithelial line connected between the rectum and vagina. Fistulas can be the outcome of acquired etiologies or congenital malformations. Recto-vaginal fistulas can also be caused due to childbirth. Obstetric injury with a fourth or a third degree perineal tear or prolonged labor with necrosis of the part or episiotomy could result in recto-vaginal fistula. Infection, breakdown of the repair, or improper repair can lead to the development of fistula. Infections caused within the recto-vaginal septum can lead to the condition. Bartholin gland infections and crypto-glandular ano-rectal abscess drains cause low recto-vaginal fistula. This explains why the recto-vaginal fistula treatment market is positioned for healthy growth during the forecast period.
Hysterectomy is performed as a result of infection caused due to fistula. Lymph granuloma venereum and tuberculosis can result in recto-vaginal fistula. Primary classification of the condition is carried out with the help of etiology, size, and location. It categorizes the criteria for recto-vaginal fistulas as complex or simple. Classification of fistula is performed to plan proper treatment and appropriate therapy. Fistulas greater than 2.5 cm in diameter are termed as large and those less than 2.5 cm are considered small. Hence, healthcare practitioners in the recto-vaginal fistula treatment market are increasing R&D to boost availability of therapeutics.
North America Helps Increase Patient Outcomes
North America is anticipated to dominate the global recto-vaginal fistula treatment market from 2021 to 2031. This can be attributed to favorable regulatory environment, rise in focus and interest in recto-vaginal fistula research & development (R&D), and government funding for life sciences research. Additionally, well-established and high quality infrastructure are driving the North America recto-vaginal fistula treatment market. The market in Asia Pacific is expected to grow at a rapid pace during the forecast period due to rise in R&D activities, increase in government initiatives for improving healthcare, and surge in focus of key players on building or strengthening presence in the region.
Governments of developing countries are making significant investments to modernize healthcare infrastructure in their respective countries, which is likely to increase access to healthcare. This is projected to fuel the demand for recto-vaginal fistula treatment.
Treatment Market: Overview
Recto-vaginal fistula is an abnormal connection between lower portions of large intestine-rectum-vagina. Causes of rectovaginal fistula include Crohn’s disease, cancer or radiation treatment in pelvic area, surgery involving vagina, perineum, rectum or anus, and injuries during childbirth.
Fistula connects to surfaces or lumens. It begins on the offending side and makes its way to an adjacent lumen or surface. It follows the easiest and shortest path to the adjacent organ. Recto-vaginal fistula starts from the rectum and extends to the vagina. It is not a healthy situation or physiological status. There is usually an underlying pathology, injury, or surgical event. Characteristics of rectovaginal fistula (RVF), such as site, size, length, activity, and symptoms, vary depending on the cause of the fistula, patient factors, and the treatment received. It is a potentially challenging surgical condition for both the patient and the healthcare team. The underlying etiology determines the method of assessment, management, and prognosis.
The frequency of recto-vaginal fistula varies according to the cause. These are typically classified by etiology, location, and size, which affect the treatment and prognosis. Recto-vaginal fistulas are divided into two groups by location:
Low RVFs are located in the lower third of the rectum and the lower half of the vagina. These are closest to the anus and are repaired with a perineal surgical approach.
High RVFs are located between the middle third of the rectum and the posterior vaginal fornix. These require a transabdominal surgical repair approach.
Most RVFs are less than 2 cm in diameter and are stratified by size:
Small: Less than 0.5 cm in diameter
Medium-sized: 0.5 to 2.5 cm in diameter
Large RVFs: Exceed 2.5 cm in diameter
Recto-vaginal Fistula Treatment Market: Drivers
Rise in prevalence of Crohn’s disease leading to the occurrence of recto-vaginal fistula drives the global recto-vaginal fistula treatment market. Crohn’s disease can be defined as an inflammatory bowel disease, wherein there is an inflammation of the digestive tract lining. Large number of women suffering from Crohn’s disease never develop recto-vaginal fistula. However, Crohn’s disease increases the risk of this condition. Hence, prevalence of recto-vaginal fistula is projected to rise during the forecast period owing to increase in incidence of Crohn’s disease.
Delivery-related injuries is the most common factor causing recto-vaginal fistulas. This includes perineum tear that extends to the bowel or an episiotomy infection, which is a surgical incision conducted to enlarge the perineum during the course of vaginal delivery. These could occur post a long, difficult, or otherwise obstructed labor. These kinds of fistula could also comprise injury to anal sphincter, the muscle rings at the end of the rectum that aid a person to hold. Hence, the incidence rate of recto-vaginal fistula is likely to increase due to rise in the rate of childbirth injuries during the forecast period.
Presence of cancerous tumor in regions, such as uterus, rectum, vagina, anal canal or cervix, can lead to development of recto-vaginal fistula. Moreover, radiation therapy undertaken to treat cancer in these body parts increases the risk of development of recto-vaginal fistulas. Past surgery in lower pelvic region, such as hysterectomy, could also result in development of recto-vaginal fistula. Therefore, rise in prevalence of pelvic cancer and surgery in lower pelvic region are projected to drive the global recto-vaginal fistula market.
Market Segmentation
In terms of type, the global recto-vaginal fistula treatment market has been classified into high rectovaginal fistula, low rectovaginal fistula, and midzone fistula
Based on end-user, the global Rectovaginal fistula treatment market has been categorized into hospitals, ambulatory surgical centers, and others
In terms of treatment, the global recto-vaginal fistula treatment market has been bifurcated into medication and surgery
Based on indication, the global recto-vaginal fistula treatment market has been divided into Crohn’s disease, delivery-related injuries, cancerous tumor treatment, and others
Each of the segments has been analyzed in detail for market trends, recent trends, and developments, drivers, restraints, opportunities, and useful insights. The Recto-vaginal fistula treatment market report provides current and expected revenue (US$ Mn) for each of these segments from 2021 to 2031, considering 2020 as the base year. The compound annual growth rate (percentage CAGR) has been provided for each segment and market from 2021 to 2031 along with market size estimations.
Treatment Market
In terms of region, the global recto-vaginal fistula treatment market has been segmented into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa
The recto-vaginal fistula treatment market in North America was valued at US$ 148.7 Mn in 2020 and is projected to reach US$ 325.8 Mn by 2031, expanding at a CAGR of 7.2% from 2021 to 2031
Growth of the market in the region can be attributed to favorable regulatory environment, rise in focus and interest in recto-vaginal fistula research & development, and government funding for life sciences research. Additionally, well-established and high quality infrastructure drives the market in North America.
Major Players
The recto-vaginal fistula treatment market report concludes with the company profiles section, which includes key information about major players in the global recto-vaginal fistula treatment market
Leading players analyzed in the report include Pfizer, Inc., GlaxoSmithKline plc, Sanofi S.A., Takeda Pharmaceutical Company Limited, Johnson & Johnson Services, Inc., W. L. Gore & Associates, Inc., Mount Sinai Hospital, Tubingen University Hospital, St. Mark’s Hospital, Apollo Hospitals Enterprise Ltd., and other prominent players
Each of these players has been profiled in the recto-vaginal fistula treatment market report based on parameters such as company overview, financial overview, business strategies, application portfolio, business segments, and recent developments
Type
- High Recto-vaginal Fistula
- Low Recto-vaginal Fistula
- Midzone Fistula
End-user
- Hospitals
- Ambulatory Surgical Center
- Others
Indication
- Crohn’s Disease
- Delivery-related Injuries
- Cancerous Tumor Treatment
- Others
Treatment
- Medication
- Antibiotics
- Biologics Therapy
- Surgery
- Sphincteroplasty Procedure
- Endorectal Advancement Flap Procedure
- Others
Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy This Premium Report From Here: https://qyresearchmedical.com/report/checkout/111471/3000
You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333
About Us
QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/